Welcome

Innate Therapeutics Limited is a public unlisted biotech company based in Auckland, NZ. The Company has designed and manufactured a unique immunomodulator microparticle technology. This technology can be used to induce the human immune system to fight certain cancers and infections, or turn off certain immune mechanisms which lead to autoimmune diseases such as Multiple Sclerosis. The same technology can be used in the design of better vaccines to potentially treat or prevent diseases such as influenza, cancer, malaria, or tuberculosis.

The microparticle at the core of this technology provides a unique delivery system for a suite of both known and novel immune system triggers or modulators. By attaching selected modulators to the microparticle, these triggers can be delivered reliably to specific cells of the immune system.

Target diseases or applications for drugs developed using this approach include:

• Auto-immune diseases such as Multiple Sclerosis;
• Certain cancers that are known to be immune-sensitive, such as prostate, colon, & renal cancer;
• Infectious diseases such as influenza and hepatitis B and C; and 
• Preventive vaccines for malaria and tuberculosis, and therapeutics vaccines for cancers.

The first drug candidate developed using this technology, MIS416, combines two well described immunostimulatory ligands or triggers - NOD2 & TLR9. MIS416, has demonstrated safety and efficacy in a number of different disease or injury models. Multiple Sclerosis has been selected as the disease target for a human Phase 2 programme due to commence in New Zealand in early 2010.